Summit Therapeutics
Stock Forecast, Prediction & Price Target

Summit Therapeutics (SMMT) stock Price Target by analysts

Last Year
Average Price Target

$35

Potential upside: 36.93%

Based on 4 analysts

Summit Therapeutics price prediction

Strike.market

What is Summit Therapeutics stock analysts` prediction?

Summit Therapeutics stock forecast: Based on 4 Wall Street analysts` predicted price targets for Summit Therapeutics in the last 3 months, the avarage price target is $35, with a high forecast of $NaN. The average price target represents a 36.93% change from the last price of $25.56.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Summit Therapeutics stock Price Target by analysts

Full breakdown of analysts given Summit Therapeutics price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Reni Benjamin
JMP Securities
0%
0/1
10 months ago $32 25.19% upside $19.96 StreetInsider
Previous targets (0)
Yigal Nochomovitz
Summit Redstone Partners
0%
0/1
11 months ago $23 -10.01% downside $20.89 StreetInsider
Previous targets (0)
Brad Canino
Stifel Nicolaus
0%
0/3
11 months ago $40 56.49% upside $24 StreetInsider
Previous targets (2)
Mitchell Kapoor
H.C. Wainwright
0%
0/1
12 months ago $45 76.05% upside $31.93 TheFly
Previous targets (0)
Brad Canino
Stifel Nicolaus
0%
0/3
over 1 year ago $14 -45.22% downside $8.69 StreetInsider
Previous targets (2)
Brad Canino
Stifel Nicolaus
0%
0/3
over 1 year ago $8 -68.70% downside $3.28 StreetInsider
Previous targets (2)

Summit Therapeutics Financial Estimates

Summit Therapeutics Revenue Estimates

Summit Therapeutics EBITDA Estimates

Summit Therapeutics Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$1.80M
 
N/A
$704.29K
 
-61.06%
$0
 
-100%
Avg: $33.70M
Low: $33.70M
High: $33.70M
avg. 0%
Avg: $12.63M
Low: $12.63M
High: $12.63M
avg. -62.52%
Avg: $89.85M
Low: $89.85M
High: $89.85M
avg. 611.43%
Avg: $416.17M
Low: $416.17M
High: $416.17M
avg. 363.15%
Net Income
 
% change YoY
$-86.14M
 
N/A
$-74.38M
 
13.65%
$-614.92M
 
-726.72%
Avg: $-140.75M
Low: $-140.75M
High: $-140.75M
avg. 77.10%
Avg: $-173.95M
Low: $-173.95M
High: $-173.95M
avg. -23.58%
Avg: $-234.43M
Low: $-234.43M
High: $-234.43M
avg. -34.77%
Avg: $-97.68M
Low: $-97.68M
High: $-97.68M
avg. 58.33%
EBITDA
 
% change YoY
$-86.18M
 
N/A
$-60.80M
 
29.45%
$1.00M
 
101.64%
Avg: $-20.22M
Low: $-20.22M
High: $-20.22M
avg. -2120.04%
Avg: $-7.57M
Low: $-7.57M
High: $-7.57M
avg. 62.52%
Avg: $-53.91M
Low: $-53.91M
High: $-53.91M
avg. -611.43%
Avg: $-249.70M
Low: $-249.70M
High: $-249.70M
avg. -363.15%
EPS
 
% change YoY
-$0.93
 
N/A
-$0.38
 
59.13%
-$0.99
 
-160.52%
Avg: -$0.23
Low: -$0.23
High: -$0.23
avg. 77.05%
Avg: -$0.28
Low: -$0.28
High: -$0.28
avg. -23.58%
Avg: -$0.38
Low: -$0.38
High: -$0.38
avg. -34.77%
Avg: -$0.16
Low: -$0.16
High: -$0.16
avg. 58.33%
Operating Expenses
 
% change YoY
$87.99M
 
N/A
$64.28M
 
-26.94%
$87.68M
 
36.40%
Avg: $600.13M
Low: $600.13M
High: $600.13M
avg. 584.41%
Avg: $224.91M
Low: $224.91M
High: $224.91M
avg. -62.52%
Avg: $1.60B
Low: $1.60B
High: $1.60B
avg. 611.43%
Avg: $7.41B
Low: $7.41B
High: $7.41B
avg. 363.15%

FAQ

What is Summit Therapeutics stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 19.27% in 2025-2028.

We have gathered data from 1 analysts. Their low estimate is -140.75M, average is -140.75M and high is -140.75M.

What is Summit Therapeutics stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 228.01% in 2025-2028.

We have gathered data from 1 analysts. Their low revenue estimate is $33.70M, average is $33.70M and high is $33.70M.

What is Summit Therapeutics stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 19.25% in 2025-2028.

We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.23, average is -$0.23 and high is $-0.22.

What is the best performing analyst?

In the last twelve months 4 analysts have been covering Summit Therapeutics stock. The most successful analyst is Reni Benjamin.